Automatic Website Traffic RSS
Cart Cell Therapy: Will First To Market Mean First To Disappoint | AutoTraffic
Wugen woos VCs, landing $115M to bring fratricide-resistant CAR-T cell therapy to market
Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the ...
read more Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007
— Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, Intermediate Capital Group (ICG), Tybourne ...
read more Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007
— WU-CART-007 achieved 91% overall response rate in global Phase 1/2 trial, substantially outperforming current standard of care — — BLA filing targeted for 2027; therapy holds potential to be first ...
read more 
Subscribe to RSS Feed
